SAMSUNG PHARMACEUTICAL.CO.,Ltd. (삼성제약(주))
KOSPI Stock Code: 001360 | DART Corp Code: 00126414
English names are as registered with DART and may differ from the Korean legal name. Use corp_code, stock_code, or business registration number to identify a company.
| English name (as registered with DART) | SAMSUNG PHARMACEUTICAL.CO.,Ltd. |
|---|---|
| Korean legal name | 삼성제약(주) |
| Alternate names | 삼성제약 |
| Market | KOSPI |
| Stock Code | 001360 |
| DART Corp Code | 00126414 |
| CEO | 정성택 대표이사 |
| Business Registration No. | 2078100726 |
| Corporate Registration No. | 1101110032568 |
| Established Date | 1929-08-15 |
| Fiscal Month | 12 |
| KSIC Industry Code | 212 |
| Address (KO) | 경기도 화성시 향남읍 제약공단4길 10 - |
| Homepage | https://www.sspharm.co.kr/ |
| source_url | https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260318001547 |
| verified_at | 2026-11-01T02:17:28.210Z |
Annual Financial Summary (KRW)
Fiscal Year: 2025 | Basis: OFS (Separate) | Currency: KRW | Filing Source: https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260318001547
| Account | FY2025 (Current) | FY2024 (Prior) |
|---|---|---|
| Revenue (매출액) | KRW 46,074,379,551 | KRW 44,294,231,025 |
| Operating Income (영업이익) | KRW -18,068,418,610 | KRW -14,828,940,152 |
| Net Income (당기순이익) | KRW 11,545,101,570 | KRW -14,092,018,358 |
| Total Assets (자산총계) | KRW 167,437,187,130 | KRW 128,451,959,179 |
| Total Liabilities (부채총계) | KRW 46,392,295,495 | KRW 22,596,614,412 |
| Total Equity (자본총계) | KRW 121,044,891,635 | KRW 105,855,344,767 |
Recent DART Filings (Last 90 Days, up to 20)
| Filed Date | Receipt No. | English Title | Korean Title | Filer |
|---|---|---|---|---|
2026-09-28 | 20260928800667 | Material Business Matters Related to Investment Decisions (진행성 핵상 마비 치료제 GV 1001의 국내 제2b/3상 임상시험계획서 변경승인 신청서 제출) | 투자판단관련주요경영사항 (진행성 핵상 마비 치료제 GV 1001의 국내 제2b/3상 임상시험계획서 변경승인 신청서 제출) | 삼성제약 |
2026-09-23 | 20260923800714 | Material Business Matters Related to Investment Decisions | 투자판단관련주요경영사항 | 삼성제약 |
2026-09-11 | 20260911800338 | Results of issuance (Voluntary Disclosure) | 유상증자또는주식관련사채등의발행결과(자율공시) | 삼성제약 |
2026-09-02 | 20260902000227 | Decision on Issuance of Convertible Bonds | 주요사항보고서(전환사채권발행결정) | 삼성제약 |
2026-08-25 | 20260825000441 | Report on significant holdings of stocks, etc. (Short form) | 주식등의대량보유상황보고서(약식) | 제스트 신기술조합 제72호 |
2026-08-14 | 20260814003546 | Semi-annual Report (2026.06) | 반기보고서 (2026.06) | 삼성제약 |
2026-08-12 | 20260812000765 | Report on Major Issues (Decision on Acquisition of Treasury Convertible Bonds before Maturity) | 주요사항보고서(자기전환사채만기전취득결정) | 삼성제약 |
Source & Disclaimer
source_url: https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260318001547 | verified_at: 2026-11-01T02:17:28.210Z
Data from Korea's Financial Supervisory Service (DART) and National Tax Service. FSS does not guarantee accuracy or completeness. Figures in KRW as filed. Not investment advice. English names are as registered with DART and may differ from the Korean legal name. Use corp_code, stock_code, or business registration number to identify a company.